
News|Articles|March 11, 2022
Life Science Executives Issue Call to Cut Business Ties with Russia
Author(s)Pharmaceutical Technology Editors
Various executives in the life sciences industry have started a petition calling for “complete economic disengagement” with Russia.
Advertisement
Various life sciences executives, including representatives from Ovid Therapeutics, Nkarta Therapeutics, and Alnylam Therapeutics, released a paper calling for fellow businesses to cease all business involvement with Russia. Until such a time that “restoration of peace and democracy [is achieved] in a sovereign Ukraine,” the authors ask that fellow businesses:
- Cease investment in Russian companies
- Reject Russian investments
- Halt collaboration or service agreements with Russian companies
- Halt trade in goods and services with Russian companies (except for food and medicines).
“We cannot look back in the future wondering whether we could have taken stronger measures.” reads the statement. “This justifies the strongest possible economic disengagement now.”
Advertisement
Related to this article

Robert Sciscento, a senior scientist at Alcami Corporation, discusses scaling up oral peptide products and what the future looks like for GLP-1 drug delivery.

Robert Sciscento, a senior scientist at Alcami Corporation, discusses formulation and delivery systems for oral peptides that might fix bioavailability challenges.

The FDA approves oral SERD giredestrant for ESR1-mutated breast cancer after a 62% risk cut, tying supply to testing ahead of a November 30, 2026 adjuvant decision.

Cole and Jaenisch explain where pharma should keep manual checks, how to vet AI skills in hires, and why self-taught AI risks GMP.

The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.

Proposal for the Public Procurement Act, adoption of a new pharmaceutical legislation, and revision of pharmacovigilance practices should improve patient access to safe and innovative medicines in Europe.

This week addressed AI accountability, CPHI award winners, NFC anticounterfeiting, first-in-class FDA approvals, and a shelved FDA voucher pilot lead this week’s roundup.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AstraZeneca Secures 2 FDA Approvals in Bladder Cancer, Myasthenia Gravis
2
Manufacturing Intelligence: AI Poisoning Demands Pharma Data Stewards
3
New Proposals and Legislation Strengthen Europe’s Position in the Pharmaceutical Arena
4
Manufacturing Intelligence: Where Pharma Should Slow AI
5


